Affimed GmbH
Technologiepark
Im Neuenheimer Feld 582
Heidelberg
69120
Germany
Tel: 49-6221-65307-0
Fax: 49-6221-65307-77
Website: http://www.affimed.com/
Email: info@affimed.com
80 articles with Affimed GmbH
-
Affimed receives $60 million up front with potential for up to $2 billion more in partnership deal with Roivant Sciences.
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
Patient Death and Life-Threatening Side Effects Cause Affimed to Hold Phase I Cancer Trials
10/9/2018
Affimed, based in Heidelberg, Germany, placed a clinical hold on its two AFM11 Phase I clinical trials. AFM11 is being evaluated in the trials for relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. -
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration
8/29/2018
GT Biopharma Inc. is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary NK-engager and Bispecific Antibody Drug Conjugate platforms.
-
Heidelberg, Germany-based Affimed NV inked a licensing deal with Switzerland-based Roche for $96 million upfront, but that was only a fraction of the entire deal. Affimed shares rocketed, more than doubling to hit $148.07.
-
Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares
2/16/2018
Jefferies LLC and Wells Fargo Securities, LLC are acting as joint book-running managers.
-
Affimed Announces Proposed Public Offering of Common Stock
2/13/2018
All of the shares in the offering will be sold by Affimed.
-
Affimed Announces Pricing of Public Offering of Common Stock
2/13/2018
The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.
-
Affimed Reports New Data for AFM13 From Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas
2/1/2018
The data demonstrate that AFM13 was well-tolerated and showed promising therapeutic efficacy both in combination with the anti-PD-1 antibody Keytruda in Hodgkin lymphoma and as monotherapy in CD30-positive lymphoma.
-
Affimed Appoints Dr. Wolfgang Fischer As Chief Operating Officer
9/13/2017
-
Affimed Reports Financial Results For Second Quarter 2017
8/1/2017
-
Affimed Presents Data On First-In-Class BCMA-Targeting Immune Cell Engager AFM26 At ASCO Annual Meeting 2017
6/6/2017
-
Affimed Announces Annual General Meeting Of Shareholders
5/22/2017
-
Affimed Reports Financial Results For First Quarter 2017
5/17/2017
-
Affimed Announces First Quarter 2017 Financial Results And Corporate Update Conference Call
5/10/2017
-
Affimed Release: Biopharma Announces Proposed Public Offering Of Common Stock
1/20/2017
-
Affimed Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform
1/11/2017
-
Affimed To Present At Upcoming Investor Conferences
9/1/2016
-
Affimed Announces Annual General Meeting Of Shareholders
5/24/2016
-
Affimed To Present At The UBS Global Healthcare Conference -- New York
5/17/2016